Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Biperiden. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 7/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.61 |
| ▸ | HTR1A | P08908 | 3/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.61 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.61 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biperiden SCHEMBL20229360 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL20229362 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL20211718 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL6775788 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL16449749 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL13898507 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL23697535 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL18281117 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL16449751 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL18281119 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1558 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| CN-118043050-A | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with solid forms of bitoldine | 迪斯克医药公司 | 2024-05-14 | — | — | CN | claimed |
| CN-114829487-B | Styrene copolymer molding compositions containing low mold deposit suitable for high gloss applications | 英力士苯领集团股份公司 | 2024-02-06 | — | — | CN | claimed |
| EP-4057999-B1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-12-13 | — | — | EP | claimed |
| CN-115066464-B | Weather resistant styrene copolymer molding compositions containing low mold deposit suitable for high gloss applications | 英力士苯领集团股份公司 | 2023-11-28 | — | — | CN | claimed |
| US-20230321008-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2023-10-12 | — | — | US | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| EP-4171545-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (FR) | 2023-05-03 | — | — | EP | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022211481-A1 | ORAL NANOPARTICLES FOR BIOACTIVE COMPOUND, AND METHOD OF PREPARING SAME | 에스엔제이 파마 인크 | 2022-10-06 | — | — | WO | claimed |
| EP-0367746-B1 | Sustained release drug-resin complexes | RICHARDSON VICKS INC (US) | 1994-02-02 | — | — | EP | claimed |
| US-5221536-A | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement | ALZA CORPORATION (US) | 1993-06-22 | — | — | US | claimed |
| US-5192550-A | Dosage form for treating central nervous system disorders | ALZA CORPORATION (US) | 1993-03-09 | — | — | US | claimed |
| EP-0527835-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT. | ALZA CORP (US) | 1993-02-24 | — | — | EP | claimed |
| EP-0526608-A1 | THERAPEUTIC AGENTS FOR THE TREATMENT OF MULTIDRUG RESISTANCE TO CANCERS. | DEBIOPHARM SA (CH) | 1993-02-10 | — | — | EP | claimed |
| EP-0380989-B1 | PLASTER FOR TRANSDERMAL ADMINISTRATION | KNOLL AG (DE) | 1992-12-23 | — | — | EP | claimed |
| WO-1992014467-A1 | THERAPEUTIC AGENTS FOR THE TREATMENT OF MULTIDRUG RESISTANCE TO CANCERS | DEBIOPHARM S.A. (CH) | 1992-09-03 | — | — | WO | claimed |
| CN-1058716-A | Do to correct the method for preparation of usefulness of muscle tonus and the use of flupirtine with active substance flupirtine preparation | ASTA MEDICA AG (DE) | 1992-02-19 | — | — | CN | claimed |
| WO-1991016885-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORPORATION (US) | 1991-11-14 | — | — | WO | claimed |
| US-5057321-A | Dosage form comprising drug and maltodextrin | ALZA CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | CHRM1 1068/4885CYP2D6 1085/4885CHRM2 2141/4885 |
| US-20230321008-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | SMPD2, SMPD1, SMPD3 | CHRM1 1851/4885CYP2D6 2493/4885CHRM2 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.